Skip to main content
. Author manuscript; available in PMC: 2014 Jul 22.
Published in final edited form as: Cancer Biol Ther. 2008 Sep 4;7(9):1418–1426. doi: 10.4161/cbt.7.9.6430

Figure 6.

Figure 6

(A) Activation of cleavage of caspase-3, caspase-9 and PARP. Whole cell lysate was used for Western blot analysis. β-actin was probed to show equal loading of total protein. (B) DLCL2 cells treated with caspase family inhibitor (Cfamily Inhibitor), Z-VAD-FMK, caspase-9 inhibitor (C9 Inhibitor), Z-LEHDFMk, caspase-3 inhibitor (C3 Inhibitor), Z-DEVD-FMK, and/or ApoG2 (1000 nM). * indicates p < 0.05 when ApoG2 and caspase inhibitor combined treatment compared with corresponding either caspase alone treatment or ApoG2 alone treatment.